Peter Seufer-Wasserthal
No más puestos en curso
Fortuna: 34 583 $ al 29/02/2024
Perfil
Peter Seufer-Wasserthal is former Director at Willow Biosciences, Inc., former Senior Vice President-Pharmaceuticals at Codexis, Inc., former Vice President-Business Development at Precigen, Inc., former Principal at Evotec SE and former Principal at Oxford Asymmetry International Plc (a subsidiary of Evotec SE), former Principal at Altus Pharmaceuticals, Inc., former Chief Commercial Officer of origenis GmbH, former Vice President-Business Development at Morphochem AG and former Chief Commercial Officer at Sestina Bio LLC.
Peter Seufer-Wasserthal received a doctorate from Graz University of Technology.
Participaciones conocidas en empresas públicas
Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
---|---|---|---|---|
WILLOW BIOSCIENCES INC.
0.34% | 28/04/2023 | 416 665 ( 0.34% ) | 34 583 $ | 29/02/2024 |
Antiguos cargos conocidos de Peter Seufer-Wasserthal.
Empresas | Cargo | Fin |
---|---|---|
WILLOW BIOSCIENCES INC. | Chief Executive Officer | 28/03/2023 |
Sestina Bio LLC
Sestina Bio LLC Packaged SoftwareTechnology Services Sestina Bio LLC operates a platform for automated synthetic biology. It provides technology centric, R&D platform to provide cutting edge solutions to sustainably feed and clothe. The firms approach is to integrate tools for genome editing, single cell biology, and machine learning to transform ability to engineer and harness biological function. The company was founded by William Wayne Colston, Jr. and is headquartered in Pleasanton, CA. | Corporate Officer/Principal | 01/08/2022 |
origenis GmbH
origenis GmbH Packaged SoftwareTechnology Services Origenis GmbH is a German biopharmaceutical company that specializes in developing small molecule medicines and diagnostics for neurodegenerative and neuroinflammatory diseases. The private company is based in Martinsried, Germany. The company's unique capabilities in drug design, compound synthesis, and characterization allow them to engineer a continuous stream of proprietary intellectual property (IP)-protected new chemical entities capable of permeating the blood-brain barrier. Origenis has a significant IP and R&D portfolio that ensures strong patent protection. Origenis was founded in 2005, and the CEO is Michael Almstetter. | Corporate Officer/Principal | 01/12/2020 |
PRECIGEN, INC. | Corporate Officer/Principal | 01/02/2018 |
Altus Pharmaceuticals, Inc.
Altus Pharmaceuticals, Inc. BiotechnologyHealth Technology Altus Pharmaceuticals, Inc. develops therapeutic products for gastrointestinal and metabolic diseases. Its principal activity is protein crystallization which is used to develop therapeutic products for gastrointestinal and metabolic diseases. The company was founded in October 1992 and is headquartered in Waltham, MA. | Corporate Officer/Principal | - |
Formación de Peter Seufer-Wasserthal.
Graz University of Technology | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 4 |
---|---|
CODEXIS, INC. | Process Industries |
PRECIGEN, INC. | Health Technology |
EVOTEC SE | Health Technology |
WILLOW BIOSCIENCES INC. | Commercial Services |
Empresas privadas | 5 |
---|---|
Oxford Asymmetry International Plc | Process Industries |
Morphochem AG
Morphochem AG Miscellaneous Commercial ServicesCommercial Services Morphochem AG discovers and develops drugs. It focuses on finding therapeutic agents to treat cancer, anti-infectives, inflammation, metabolic disorders and infectious diseases, with particular emphasis on enzyme inhibitors. The company has developed an integrated chemical genomics drug discovery engine that it is applying in third party research programs and for building its own fully owned pipeline. Morphochem is headquartered in Munich, Germany. | Commercial Services |
Altus Pharmaceuticals, Inc.
Altus Pharmaceuticals, Inc. BiotechnologyHealth Technology Altus Pharmaceuticals, Inc. develops therapeutic products for gastrointestinal and metabolic diseases. Its principal activity is protein crystallization which is used to develop therapeutic products for gastrointestinal and metabolic diseases. The company was founded in October 1992 and is headquartered in Waltham, MA. | Health Technology |
origenis GmbH
origenis GmbH Packaged SoftwareTechnology Services Origenis GmbH is a German biopharmaceutical company that specializes in developing small molecule medicines and diagnostics for neurodegenerative and neuroinflammatory diseases. The private company is based in Martinsried, Germany. The company's unique capabilities in drug design, compound synthesis, and characterization allow them to engineer a continuous stream of proprietary intellectual property (IP)-protected new chemical entities capable of permeating the blood-brain barrier. Origenis has a significant IP and R&D portfolio that ensures strong patent protection. Origenis was founded in 2005, and the CEO is Michael Almstetter. | Technology Services |
Sestina Bio LLC
Sestina Bio LLC Packaged SoftwareTechnology Services Sestina Bio LLC operates a platform for automated synthetic biology. It provides technology centric, R&D platform to provide cutting edge solutions to sustainably feed and clothe. The firms approach is to integrate tools for genome editing, single cell biology, and machine learning to transform ability to engineer and harness biological function. The company was founded by William Wayne Colston, Jr. and is headquartered in Pleasanton, CA. | Technology Services |